Quarterly ResultMay 5, 2026, 04:15 PM
OnKure Therapeutics Q1 Net Loss $15.2M; $192M Cash; New Drug Candidates
AI Summary
OnKure Therapeutics reported its first quarter 2026 financial results, including a net loss of $15.2 million, an improvement from $15.9 million in the prior year. The company significantly strengthened its financial position by closing a $150 million private placement, bringing its cash and cash equivalents to $192.1 million, expected to fund operations into 2029. Strategically, OnKure nominated two new next-generation PI3Ka pan-mutant selective inhibitor candidates, OKI-355 for vascular anomalies and OKI-345 for breast cancer, with IND submissions planned for the first half of 2027.
Key Highlights
- OnKure nominated OKI-355 as a next-generation PI3Ka pan-mutant selective inhibitor candidate for vascular anomalies.
- OnKure nominated OKI-345 as a next-generation PI3Ka pan-mutant selective inhibitor candidate for breast cancer.
- Closed a $150 million private placement to advance PI3Ka pan-mutant programs into clinical development in 2027.
- Cash and cash equivalents were $192.1 million as of March 31, 2026, expected to fund operations into 2029.
- Research and development expenses decreased to $11.7 million in Q1 2026 from $13.0 million in Q1 2025.
- General and administrative expenses decreased to $3.9 million in Q1 2026 from $4.0 million in Q1 2025.
- Net loss for Q1 2026 was $15.2 million, or $1.11 per share, compared to $15.9 million, or $1.19 per share, in Q1 2025.
- Plans to submit IND applications for OKI-355 and OKI-345 to the FDA in the first half of 2027.